

IMPACT FACTOR 5.2

Indexed in: PubMed



an Open Access Journal by MDPI

Protein Kinases and Cancers

Guest Editors:

Prof. Dr. Richard Bayliss

Astbury Centre for Structural Molecular Biology, School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK

Dr. Sharon Yeoh

School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK

Deadline for manuscript submissions:

closed (15 February 2019)

Message from the Guest Editors

function The regulation of protein through phosphorylation is a major component of cellular signalling pathways, such as those that govern cell cycle progression, control gene expression or determine whether a cell survives or dies. In humans, the phosphorylation of proteins is catalysed by over 500 protein kinases, most of which specifically modify either Ser/Thr or Tyr side chains. Their catalytic activities are regulated through molecular mechanisms that are dysregulated in cancer by mutations that cause uncontrolled kinase activity. Tumours that harbour such mutations can be addicted to the activity of a single protein kinase, and kinase inhibitors have recently become a successful class of cancer therapeutic.

We aim to stimulate discussion by bringing together expert opinion and new science from across the field in a Special Issue of *Cancers*. We welcome submissions that cover any relevant topic, including protein kinases and non-oncogene addiction; non-canonical protein kinases; protein kinase structure and dynamics; mechanisms of dysregulation in cancer; small molecule inhibitors of protein kinases; allostery in protein kinases; the future of protein kinase therapeutics.













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us